A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells - PubMed (original) (raw)
A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells
Courtney M Lappas et al. J Immunol. 2005.
Abstract
Incubation of purified C57BL/6 murine CD4(+) T lymphocytes with anti-CD3 mAb serves as a model of TCR-mediated activation and results in increased IFN-gamma production and cell surface expression of CD25 and CD69. We demonstrate here that signaling through the TCR causes a rapid (4-h) 5-fold increase in A(2A) adenosine receptor (AR) mRNA, which is correlated with a significant increase in the efficacy of A(2A)AR-mediated cAMP accumulation in these cells. A(2A)AR activation reduces TCR-mediated production of IFN-gamma by 98% with a potency order of 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl]prop-2-ynyl}cyclohexanecarboxylic acid methyl ester (ATL146e; EC(50) = 0.19 +/- 0.03 nM) > 4-{3-[6-amino-9-(5-cyclopropyl-carbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl]prop-2-ynyl}piperidine-1-carboxylic acid methyl ester (ATL313; 0.43 +/- 0.06 nM) > 5'-N-ethylcarboxamidoadenosine (3.5 +/- 0.77 nM) > 2-[4-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamidoadenosine (CGS21680; 7.2 +/- 1.4 nM) >> N(6)-cyclohexyladenosine (110 +/- 33 nM) > 2-chloro-N(6)-(3-iodobenzyl)-5'-N-methylcarboxamide (390 +/- 160 nM), similar to the potency order to compete for radioligand binding to the recombinant murine A(2A)AR but not the A(3)AR. The selective A(2A)AR antagonist, 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)phenol (ZM241385), inhibits the effect of ATL146e with a pA(2) of 0.34 nM and also inhibits the effects of N(6)-cyclohexyl-adenosine and 2-chloro-N(6)-(3-iodobenzyl)-5'-N-methylcarboxamide. In CD4(+) T cells derived from A(2A)AR(-/-) and A(2A)AR(+/-) mice, the IFN-gamma release response to ATL146e is reduced by 100 and 50%, respectively, indicative of a gene dose effect. The response of T cells to the phosphodiesterase inhibitor, 4-(3'-cyclopentyloxy-4'-methoxyphenyl)-2-pyrrolidone (rolipram), is not affected by A(2A)AR deletion. We conclude that the rapid induction of the A(2A)AR mRNA in T cells provides a mechanism for limiting T cell activation and secondary macrophage activation in inflamed tissues.
Similar articles
- Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.
Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. Sullivan GW, et al. Br J Pharmacol. 2001 Mar;132(5):1017-26. doi: 10.1038/sj.bjp.0703893. Br J Pharmacol. 2001. PMID: 11226132 Free PMC article. - Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction.
Day YJ, Marshall MA, Huang L, McDuffie MJ, Okusa MD, Linden J. Day YJ, et al. Am J Physiol Gastrointest Liver Physiol. 2004 Feb;286(2):G285-93. doi: 10.1152/ajpgi.00348.2003. Am J Physiol Gastrointest Liver Physiol. 2004. PMID: 14715520 - Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction.
Murphree LJ, Sullivan GW, Marshall MA, Linden J. Murphree LJ, et al. Biochem J. 2005 Nov 1;391(Pt 3):575-80. doi: 10.1042/BJ20050888. Biochem J. 2005. PMID: 16022683 Free PMC article. - The role of the adenosinergic system in lung fibrosis.
Della Latta V, Cabiati M, Rocchiccioli S, Del Ry S, Morales MA. Della Latta V, et al. Pharmacol Res. 2013 Oct;76:182-9. doi: 10.1016/j.phrs.2013.08.004. Epub 2013 Aug 28. Pharmacol Res. 2013. PMID: 23994158 Review. - Regulation of lymphocyte function by adenosine.
Linden J, Cekic C. Linden J, et al. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2097-103. doi: 10.1161/ATVBAHA.111.226837. Epub 2012 Jul 5. Arterioscler Thromb Vasc Biol. 2012. PMID: 22772752 Free PMC article. Review.
Cited by
- The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies.
Wang L, Zhang J, Zhang W, Zheng M, Guo H, Pan X, Li W, Yang B, Ding L. Wang L, et al. Acta Pharm Sin B. 2024 May;14(5):1951-1964. doi: 10.1016/j.apsb.2023.12.004. Epub 2023 Dec 16. Acta Pharm Sin B. 2024. PMID: 38799637 Free PMC article. Review. - Low Density Lipoprotein Cholesterol Decreases the Expression of Adenosine A2A Receptor and Lipid Rafts-Protein Flotillin-1: Insights on Cardiovascular Risk of Hypercholesterolemia.
Chaptal MC, Maraninchi M, Musto G, Mancini J, Chtioui H, Dupont-Roussel J, Marlinge M, Fromonot J, Lalevee N, Mourre F, Beliard S, Guieu R, Valero R, Mottola G. Chaptal MC, et al. Cells. 2024 Mar 11;13(6):488. doi: 10.3390/cells13060488. Cells. 2024. PMID: 38534331 Free PMC article. - Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application.
Wang R, Liu Z, Wang T, Zhang J, Liu J, Zhou Q. Wang R, et al. Front Immunol. 2024 Jan 29;15:1320244. doi: 10.3389/fimmu.2024.1320244. eCollection 2024. Front Immunol. 2024. PMID: 38348050 Free PMC article. Review. - Pre-treatment inflamed tumor immune microenvironment is associated with FOLFIRINOX response in pancreatic cancer.
Gao Z, Kang SW, Erstad D, Azar J, Van Buren G, Fisher W, Sun Z, Rubinstein MP, Lee HS, Camp ER. Gao Z, et al. Front Oncol. 2023 Nov 23;13:1274783. doi: 10.3389/fonc.2023.1274783. eCollection 2023. Front Oncol. 2023. PMID: 38074633 Free PMC article. - Adenosine, bridging chronic inflammation and tumor growth.
Chen L, Alabdullah M, Mahnke K. Chen L, et al. Front Immunol. 2023 Oct 31;14:1258637. doi: 10.3389/fimmu.2023.1258637. eCollection 2023. Front Immunol. 2023. PMID: 38022572 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials